About us

Member-of-Biotech-AustriaAcquired by Sanofi on December 2021, Origimm (‘Origins of Immunity’) is an Austrian biotechnology company, which specializes in the discovery of antigens and dermatological drug targets against diseases induced by skin colonizing bacteria.

The company uses its proprietary technology to identify highly protective antigens and therapeutic targets by reverse functional screening, thereby significantly improving the success in the selection of the most effective active ingredients and products for maintaining skin health, and for preventing or treating disease.

continue reading…